GlobalData AGM on April 28, 2026, Could Spark Re-rating If Margin Recovery and Growth Gains Momentum

The immediate catalyst is the release of GlobalData's 2025 annual report. The next Annual General Meeting is scheduled for April 28, 2026, setting the stage for shareholder debate. The numbers present a stark tension. Total revenue grew a solid 13% year-on-year to £322.1 million, but the core organic growth was minimal, with underlying revenue rising just 1%. More concerning, adjusted EBITDA declined 6% to £110.2 million, dragging the margin down to 34% from 41%.

The company attributes this squeeze to a strategic pivot. Management announced it will ease up on M&A activity outside its high-margin healthcare division after acquisitions made over the prior two years took longer than initially anticipated to integrate. This creates a near-term overhang. The planned investment and integration costs are directly cited as a reason for the EBITDA drop. While the positive AGM date offers a clear event for scrutiny, the strategic shift away from growth through acquisition may temporarily outweigh any optimism from the meeting itself.

Financial Impact: The Margin and Growth Trade-Off

The financial numbers reveal a company in a deliberate trade-off. The adjusted EBITDA margin of 34% is a clear miss against the stated target of 40%, indicating that the strategic investment and integration costs are taking a tangible bite out of profitability. This is the direct cost of the pivot away from aggressive M&A growth.

On the growth front, the picture is equally mixed. While total revenue grew 13% to £322.1 million, that was driven largely by acquisitions. The core organic engine remains weak, with underlying revenue rising just 1%. The more telling metric is underlying Contracted Forward Revenue, which grew 3% and provides visibility into the next year. This slow pace of contracted growth suggests the new "solutions-led" sales model is gaining traction, but not yet at a rate that would support a rapid re-rating.

The statutory profit story adds another layer of complexity. Profit before tax rose 26% to £69.2 million, but this includes a non-cash share-based payment credit of £20.5 million. Strip that out, and the underlying earnings story is less robust. The company is effectively using accounting credits to offset real operational pressures, which raises questions about the sustainability of the reported bottom-line growth.

The bottom line is that the reported figures do not yet support a sustainable model for rapid expansion. The margin pressure is real and ongoing, while organic growth is barely above zero. The company is choosing a path of internal strengthening over external acquisition, which may be the right long-term call but creates a near-term overhang for the stock. The market will need to see a clear inflection in both margin recovery and underlying revenue growth before these numbers look like a catalyst for a re-rating.

Valuation and Scenario Setup

The stock's steep decline sets the stage for a binary setup. With shares down 56.82% over the past year and trading near the low end of its 52-week range, the market has already priced in a significant slowdown. This creates a potential mispricing if the company can demonstrate that the strategic pivot is working faster than feared. The primary near-term catalyst is the April 28, 2026 AGM, where management will likely provide 2026 guidance and address the timeline for margin recovery.

The investment case hinges on two competing scenarios. The bullish path assumes the company's "solutions-led" sales model gains traction quickly, driving underlying revenue growth above the 1% seen in 2025 and accelerating the realization of revenue synergies from recent acquisitions. This would allow the business to hit its stated goal of returning the adjusted EBITDA margin to 40%, even as it eases up on M&A. The market's disconnect, as noted by analysts, suggests the stock could pop on any evidence of an inflection.

The bearish risk is that the operational transformation takes longer than expected. The strategic shift to organic growth in non-healthcare, as outlined by CEO Mike Danson, is a direct response to acquisitions that took longer than initially anticipated to integrate. If this integration drag persists, it could delay the margin improvement and keep underlying growth muted, validating the market's pessimism. The company's own note that revenue synergies remain a significant opportunity underscores this uncertainty.

For now, the stock's low valuation offers a margin of safety, but also reflects deep skepticism. The AGM will be a critical event to test which scenario is more likely. A clear, confident 2026 outlook could spark a re-rating; a vague or cautious one may confirm the downtrend. The setup is one of high risk, high potential reward, centered on a single upcoming event.